Fig. 4: A/BOL13 provides reduced protection against influenza-like illness. | npj Vaccines

Fig. 4: A/BOL13 provides reduced protection against influenza-like illness.

From: Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition

Fig. 4: A/BOL13 provides reduced protection against influenza-like illness.

Change in ferret core body temperature was measured hourly from pre-vaccination to study termination. Change in individual animal body temperature versus baseline (Δtemp [°C]) following wild-type challenge for all animals is shown in a (A/BOL13) and b (A/NC99). Curves are spline fits to hourly data. Individual fever values are summarized in c (A/BOL13) and d (A/NC99). Temperature traces from two animals in the A/BOL13, 3.0 log10 FFU, monovalent LAIV-dose group were corrupted and had to be excluded from this analysis. Bar graphs show fever values from individual animals (symbols), four animals per dose group. Fever temperatures shown are the average increase over baseline body temperature post-challenge, as described in “Methods”. Columns and error bars show group median and interquartile range. Statistical assessment of fever was conducted using two-way analysis of variance with Sidak’s post-test correcting for multiple comparisons. All vaccinated groups were compared with unvaccinated controls. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. LAIV live attenuated influenza vaccine, A/BOL13 A/Bolivia/559/2013, A/NC99 A/New Caledonia/20/1999, FFU fluorescent focus units.

Back to article page